新冠病毒病2019（COVID-19）大流行已经使卫生保健系统超出其能力范围，导致缺乏适当的癌症治疗方案。本研究的目的是评估疫情相关限制对口腔癌患者辅助治疗方案的影响。在这个高强度的时期内，手术治疗时间在2020年2月至7月之间的口腔癌患者，预定接受COVID-19相关限制期间开方的辅助治疗方案（I组），被纳入了本研究。数据与在限制制度施行前6个月同样接受辅助治疗方案的一组病人（II组）进行匹配，以匹配住院时间和开方的辅助治疗方案类型。获得了人口统计学和治疗方案特定的细节，包括在获得开方治疗过程中遇到的困难。使用回归模型进行比较，以确定影响接受辅助治疗推迟的因素。共考虑了116名口腔癌患者进行分析，其中69％（n = 80）只接受放射治疗，31％（n = 36）同时接受化疗和放射治疗。平均住院时间为13天。在I组中，29.3％（n = 17）的患者根本没有接受任何形式的预定辅助治疗，比II组高2.43倍（P = 0.038）。疾病相关因素都没有明显预测推迟接受辅助治疗。这些推迟中，76.47％（n = 13）出现在限制施行的最初阶段，最常见原因是无法预约（47.1％，n = 8），其次是无法到达治疗中心（23.5％，n = 4）和兑换费用（23.5％，n = 4）。在手术后8周以后推迟接受放射治疗开始的患者数量在I组（n = 29）中是II组（n = 15）的两倍（P = 0.012）。本研究突出了COVID-19限制对口腔癌管理的涟漪效应的一小部分，需要决策者采取实际行动来应对这些挑战。

The ongoing coronavirus disease 2019 (COVID-19) pandemic has hard-pressed the health care systems beyond their capabilities, causing a lack of appropriate cancer treatment delivery. The aim of this study was to assess the impact of pandemic-related restrictions on adjuvant therapy delivery for oral cancer patients during these demanding times.Oral cancer patients who were operated on between February and July 2020 and scheduled to receive prescribed adjuvant therapy during the COVID-19-related restrictions (Group I) were included in the study. The data were matched for the length of hospital stay and type of prescribed adjuvant therapy, with a set of patients who were similarly managed 6 months preceding the restrictions (Group II). Demographic and treatment-specific details, including inconveniences faced in procuring prescribed treatment, were obtained. Factors associated with delay in receiving adjuvant therapy were compared using regression models.A total of 116 oral cancer patients were considered for analysis, comprising 69% (n = 80) adjuvant radiotherapy alone and 31% (n = 36) concurrent chemoradiotherapy. The mean hospital stay was 13 days. In Group I, 29.3% (n = 17) of patients were not able to receive any form of their prescribed adjuvant therapy at all, which was 2.43 times higher than Group II (P = 0.038). None of the disease-related factors significantly predicted delay in receiving adjuvant therapy. Of the delay, 76.47% (n = 13) was present during the initial part of the restrictions, with the most common reason being unavailability of appointments (47.1%, n = 8), followed by inability to reach treatment centers (23.5%, n = 4) and redeem reimbursements (23.5%, n = 4). The number of patients who were delayed the start of radiotherapy beyond 8 weeks after surgery was double in Group I (n = 29) than in Group II (n = 15; P = 0.012).This study highlights a small part of the rippling effect the COVID-19 restrictions have on oral cancer management and pragmatic actions may be needed by policymakers to deal with such challenges.